KOSUNI KOREA
Korean News in English
Business

Management Stock Criteria and Investment Strategies: The Impact of Listed Companies' Financial Health

Published September 20, 2026 · 3 views
Management Stock Criteria and Investment Strategies: The Impact of Listed Companies' Financial Health

Management Stock Criteria and Delisting Risk

Even 'strong companies' on the KOSDAQ market face delisting threats. Recent market trends show that settlement funds have hit a six-month low, with companies under management stock designation facing delisting risks if financial conditions worsen for two consecutive years.

Recent News on Management Stock Designation and Delisting

More companies in the KOSPI and KOSDAQ markets are being designated as management stocks due to deteriorating financial health, particularly those facing issues like capital erosion or accounting fraud. The pharmaceutical and biotech sectors have seen heightened concerns.

Management stock designation occurs due to factors such as insufficient market capitalization or financial deterioration. With tightened delisting criteria, over 100 companies now face delisting fears. If a company fails to meet sales targets for two consecutive years after being designated, it risks delisting.

Financial Deterioration of Listed Companies and Management Stock Designation

Zyung Tech faces management stock concerns amid rumors of a change in control, while SeniGen is struggling to maintain listing due to market capitalization restrictions after its technology-based listing expired. Esfolitech missed the golden opportunity by remaining inactive despite facing management stock designation risks.

Regulators warn against management stock designation resulting from lack of business strategy or financial deterioration. A recent six-month grace period policy has been introduced, aiming to stabilize the market while strengthening delisting criteria.

관리종목 선정 기준과 투자 전략: 상장사의 재무 상태가 미치는 영향 설명 이미지

Detailed Management Stock Designation Criteria

KOSDAQ companies with sales below 300 million won may face management stock designation, and if they fail to meet sales targets for two consecutive years, delisting risks emerge. This reflects an increase in cases where companies are designated due to failed investment attraction or financial deterioration.

ANC&N has shown positive signs toward resolving its management stock status, while Shapheron faces potential designation due to legal loss risks. Invenia had trading halted during the day due to management stock designation concerns.

Strengthened Delisting Criteria and Grace Period Policy

The Financial Services Commission is tightening management stock criteria to prevent financial deterioration among listed companies, while introducing a six-month grace period to stabilize the market. This aligns with reports that one in ten listed companies now faces potential management stock designation.

Exchanges are enhancing post-listing oversight for special listing companies and proposing 'value-up' disclosures as a way to delay delisting. Companies designated as management stocks may face delisting risks due to financial deterioration, and the Financial Supervisory Service has begun prioritizing certain firms for review.

Crisis Awareness in Pharmaceutical and Biotech Sectors

The pharmaceutical and biotech sectors are experiencing heightened crisis awareness due to tightened delisting criteria. Reports indicate that warnings about management stock designation and potential delisting are not merely cautionary but reflect real risks.

Notably, even 'strong companies' on KOSDAQ face delisting threats, with market settlement funds hitting a six-month low. This reflects a combination of failed investment attraction and financial deterioration.

Response Strategies After Management Stock Designation

Designated management stock companies can delay delisting through 'value-up' disclosures. This strategy aligns with the criteria that determine designation based on financial health, particularly if sales targets are missed for two consecutive years.

Zyung Tech and SeniGen are attempting to mitigate delisting risks through control transfers or enhanced post-listing oversight for special listing companies. However, Esfolitech missed its golden opportunity by remaining inactive despite management stock designation concerns.

Key Information to Verify

It is essential to verify that a company faces delisting risk if it experiences two consecutive years of financial deterioration after being designated as a management stock. For KOSDAQ companies, this applies when sales fall below 300 million won, with potential delisting if sales targets are missed for two consecutive years.

Regulators warn against management stock designation due to lack of business strategy or financial deterioration, and the recent six-month grace period policy is influencing market dynamics. Reports indicate that one in ten listed companies faces potential management stock designation.

Frequently Asked Questions

What are the criteria for management stock designation?

Management stock designation occurs due to factors such as insufficient market capitalization or financial deterioration. For KOSDAQ companies, designation is possible if sales fall below 300 million won.

How can a company avoid delisting risk?

A company may delay delisting through 'value-up' disclosures. Other strategies include control transfers or improving financial health to resolve management stock status.

Why is crisis awareness high in the pharmaceutical and biotech sectors?

The pharmaceutical and biotech sectors face higher risks of management stock designation and delisting due to technology-based listings, particularly when facing capital erosion or accounting fraud issues.

Frequently Asked Questions

Recent reports indicate that even 'strong companies' on KOSDAQ are at risk of delisting. Management stock designation criteria and recent news on delisting risks show an increase in cases where financial deterioration leads to management stock designation and potential delisting, especially due to capital erosion or accounting fraud. The pharmaceutical and biotech sectors have heightened concerns.

Management stock designation after two consecutive years of financial deterioration poses a delisting risk. For KOSDAQ companies, this applies when sales fall below 300 million won, with potential delisting if sales targets are missed for two consecutive years. Regulators warn against management stock designation due to lack of business strategy or financial deterioration, and the recent six-month grace period policy aims to stabilize the market.

Investors must closely monitor management stock criteria and delisting-related information, as proactive measures against financial deterioration risks are crucial. This serves as a serious warning about listed companies' business strategies and financial health.

Read More Related Articles

You can view similar articles on this topic in one place.

View Related Articles

FAQ

What are the criteria for management stock designation?

Management stock designation occurs due to factors such as insufficient market capitalization or financial deterioration. For KOSDAQ companies, designation is possible if sales fall below 300 million won.

How can a company avoid delisting risk?

A company may delay delisting through 'value-up' disclosures. Other strategies include control transfers or improving financial health to resolve management stock status.

Why is crisis awareness high in the pharmaceutical and biotech sectors?

The pharmaceutical and biotech sectors face higher risks of management stock designation and delisting due to technology-based listings, particularly when facing capital erosion or accounting fraud issues.

Korean Source

This article is an English localization of a Korean-language report from BlogScore. Original: 관리종목 선정 기준과 투자 전략: 상장사의 재무 상태가 미치는 영향